Scholarlink

Background <p>To evaluate the use of hydroxychloroquine (HCQ) and its impact on the Health Assessment Questionnaire disability index(HAQ-DI) and the Cochin Hand Function Status(CHFS) in a large Systemic Sclerosis (SSc) cohort.</p> Methods <p>SSc patients from the European Scleroderma Trials and Research (EUSTAR) database treated with HCQ for at least 6 months were evaluated and compared to a matched group of SSc patients not using HCQ. Demographic and clinical data, concomitant drugs, HAQ-DI and CHFS (at least 2 evaluations) were recorded and were the outcome variables of interest. Statistical analysis was performed using propensity score matching for age, gender, disease duration, corticosteroids, immunosuppressives, vasoactive drugs in a 3:1 control: HCQ ratio. Standard descriptive statistics and Student’s t-test and Chi-square test were used to assess the propensity-matched groups.</p> Results <p>Out of 17,805 SSc patients evaluated, 468 (2.6%) used HCQ and constituted the HCQ group. Among them, 50 (10.7%) had at least a baseline and follow-up HAQ-DI evaluation and 44 (9.4%) had at least a baseline and follow-up CHFS evaluation.</p> <p>Propensity matching assured that patients were matched for female gender (HCQ vs. control 92.0% vs. 85.3%), mean age (49.8 vs. 50.0 years) disease duration (8.3 vs. 9.1 years), limited disease (55.3 vs. 62.6%) as well as background medications (all <i>P</i> &gt; 0.1). We did not find any significant differences among the two groups in the change of HAQ-DI or CHFS, over up to 365 days (all <i>P</i> &gt; 0.05).</p> Conclusions <p>Results from the EUSTAR registry showed that HCQ was used by 2.6% of SSc patients. HCQ use did not improve the HAQ-DI, or CHFS when comparing HCQ users to non-HCQ users.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The effect of hydroxychloroquine on activities of daily living and hand function in systemic sclerosis: results from an analysis of the EUSTAR cohort

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月27日

查看全文
  • S. Bellando-Randone,
  • H. Wilhalme,
  • C. Bruni,
  • L. Czirjak,
  • O. Distler,
  • Y. Allanore,
  • G. Cuomo,
  • C. Denton,
  • F. Del Galdo,
  • A. M. Gheorghiu,
  • V. Riccieri,
  • U. Walker,
  • M. E. Truchetet,
  • M. C. Vonk,
  • I. Foeldvari,
  • M. Matucci-Cerinic,
  • D. E. Furst,
  • Marco Matucci Cerinic,
  • Ulrich Walker,
  • Florenzo Iannone,
  • Serena Guiducci,
  • Radim Becvar,
  • Gabriele Valentini,
  • Elise Siegert,
  • C. Montecucco,
  • Patricia E. Carreira,
  • Carlo Chizzolini,
  • Eugene J. Kucharz,
  • Andrea Doria,
  • Pr Dominique Farge Bancel,
  • Roger Hesselstrand,
  • Alexandra Balbir-Gurman,
  • Raffaele Pellerito,
  • Cristian Caimmi,
  • Christopher Denton,
  • Nemanja Damjanov,
  • Jörg Henes,
  • Vera Ortiz-Santamaria Granollers,
  • Stefan Heitmann,
  • Maria João Salvador,
  • Bojana Stamenkovic,
  • Carlo Francesco Selmi,
  • Ariane Herrick,
  • Ulf MüllerLadner,
  • Merete Engelhart,
  • Valeria Riccieri,
  • Ruxandra Maria Ionescu,
  • Ana Maria Gheorghiu,
  • Cord Sunderkötter,
  • Jörg Distler,
  • Francesca Ingegnoli,
  • Luc Mouthon,
  • Vanessa Smith,
  • Francesco Paolo Cantatore,
  • Susanne Ullman,
  • Maria Rosa Pozzi,
  • Piotr Wiland,
  • Marie Vanthuyne,
  • Brigitte Krummel-Lorenz,
  • Petra Saar,
  • Kristine Herrmann,
  • Ellen De Langhe,
  • Branimir Anic,
  • Marko Baresic,
  • Miroslav Mayer,
  • Sule Yavuz,
  • Carolina de Souza Müller,
  • Thierry Zenone,
  • Alessandro Mathieu,
  • Alessandra Vacca,
  • Kamal Solanki,
  • Edoardo Rosato,
  • Fahrettin Oksel Figen Yargucu,
  • Cristina-Mihaela Tanaseanu,
  • Rosario Foti,
  • Daniel E. Furst,
  • Peter Villiger Sabine Adler,
  • Paloma García de la Peña Lefebvre,
  • Jorge Juan González Martín,
  • Ira Litinsky,
  • Francesco Del Galdo,
  • Goda Seskute,
  • Lesley Ann Saketkoo,
  • Eduardo Kerzberg,
  • Ivan Castellví,
  • François Spertini,
  • Vivien M. Hsu,
  • Thierry Martin,
  • Tim Schmeiser,
  • Dominik Majewski,
  • Vera Bernardino,
  • Piercarlo Sarzi Puttini

摘要

Background

To evaluate the use of hydroxychloroquine (HCQ) and its impact on the Health Assessment Questionnaire disability index(HAQ-DI) and the Cochin Hand Function Status(CHFS) in a large Systemic Sclerosis (SSc) cohort.

Methods

SSc patients from the European Scleroderma Trials and Research (EUSTAR) database treated with HCQ for at least 6 months were evaluated and compared to a matched group of SSc patients not using HCQ. Demographic and clinical data, concomitant drugs, HAQ-DI and CHFS (at least 2 evaluations) were recorded and were the outcome variables of interest. Statistical analysis was performed using propensity score matching for age, gender, disease duration, corticosteroids, immunosuppressives, vasoactive drugs in a 3:1 control: HCQ ratio. Standard descriptive statistics and Student’s t-test and Chi-square test were used to assess the propensity-matched groups.

Results

Out of 17,805 SSc patients evaluated, 468 (2.6%) used HCQ and constituted the HCQ group. Among them, 50 (10.7%) had at least a baseline and follow-up HAQ-DI evaluation and 44 (9.4%) had at least a baseline and follow-up CHFS evaluation.

Propensity matching assured that patients were matched for female gender (HCQ vs. control 92.0% vs. 85.3%), mean age (49.8 vs. 50.0 years) disease duration (8.3 vs. 9.1 years), limited disease (55.3 vs. 62.6%) as well as background medications (all P > 0.1). We did not find any significant differences among the two groups in the change of HAQ-DI or CHFS, over up to 365 days (all P > 0.05).

Conclusions

Results from the EUSTAR registry showed that HCQ was used by 2.6% of SSc patients. HCQ use did not improve the HAQ-DI, or CHFS when comparing HCQ users to non-HCQ users.